Demant A/S (OTCMKTS:WILYY) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Demant A/S Unsponsored ADR (OTCMKTS:WILYY) saw unusually-strong trading volume on Thursday . Approximately 1,400 shares were traded during mid-day trading, an increase of 165% from the previous session’s volume of 529 shares.The stock last traded at $22.50 and had previously closed at $22.58.

Analysts Set New Price Targets

A number of analysts have recently issued reports on WILYY shares. Sanford C. Bernstein downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. UBS Group downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Morgan Stanley raised Demant A/S from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 23rd. Finally, Zacks Research upgraded Demant A/S to a “hold” rating in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Demant A/S Price Performance

The company’s 50-day simple moving average is $20.38 and its 200-day simple moving average is $17.40. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 1.65.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.